Manufacturer record
Rivpra Formulation Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
29 batches manufactured by Rivpra Formulation Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality between January 2022 and September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: L-2507011, Bromhexine Hydrochloride, Terbutaline Sulphate, Guaiphenesin & Menthol Syrup (exp Jun 2027). RDTL, Chandigarh (CDSCO lab) found it not of standard quality: The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Bromhexine Hydrochloride, Terbutaline Sulphate. Listed in the September 2026 alert.
Records by type
29 records linked to Rivpra Formulation Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
0Banned or prohibited
0Recalled or suspended
29Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
29
NSQ batches since 2022
17
Products affected
Assay
Most common failure
Sep 2026
Latest alert
Flagged batches per year
2022 · 32023 · 22024 · 32025 · 62026 · 15
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Bromhexine Hydrochloride, Terbutaline Sulphate, Guaiphenesin & Menthol Syrup | Batch L-2507011Mfg Jul 2025 · Exp Jun 2027 | The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Bromhexine Hydrochloride, Terbutaline SulphateAssay | RDTL, ChandigarhCDSCO lab | Sep 2026 |
| Sodium Bicarbonate Tablets USP 1000 mg | Batch T-2502219Mfg Feb 2025 · Exp Jan 2027 | The sample does not conform to claim as per USP 2025 in respect to the Test of Description.Description | RDTL, ChandigarhCDSCO lab | Aug 2026 |
| Sodium Bicarbonate Tablets IP 500 mg | Batch T-2603386Mfg Mar 2026 · Exp Feb 2028 | The sample does not conform to the IP standards with respect to the test DisintegrationDisintegration | DTL, ThrissurState lab | Aug 2026 |
| Sodium Bicarbonate Tablets I.P. 1000 mg | Batch T-2509202Mfg Sep 2025 · Exp Aug 2027 | The sample does not conform to I.P (Addendum 2024) with respect to the Test of DisintegrationDisintegration | CDTL, IndoreCDSCO lab | Jul 2026 |
| Glimepiride Tablets IP 4mg | Batch T2512152Mfg Dec 2025 · Exp Nov 2027 | Does not conform to IP Standards with respect to Dissolution TestDissolution | Food & Drugs Laboratory Bambolim, GoaState lab | Jul 2026 |
| Bromhexine Hydrochloride, Terbutaline Sulphate, Guaiphenesin & Menthol Syrup | Batch L-2601029Mfg Jan 2026 · Exp Dec 2027 | The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Bromhexine Hydrochloride.Assay | RDTL, ChandigarhCDSCO lab | Jun 2026 |
| Teneligliptin & Metformin Hydrochloride Extended Release tablets IP | Batch T-2503098Mfg Mar 2025 · Exp Feb 2027 | The sample does not conform to I.P. with respect to the Dissolution and Assay of TeneligliptinAssay | CDL, KolkataCDSCO lab | May 2026 |
| Hydroxychloroquine Sulphate Tablets IP 200mg | Batch T-2511405Mfg Nov 2025 · Exp Oct 2027 | Dissolution as per IPDissolution | DTL, ThiruvananthapuramState lab | Mar 2026 |
| Ambroxol Hydrochloride, Guaiphenesin & Terbutaline Sulphate Syrup | Batch L-2508006Mfg Aug 2025 · Exp Jul 2027 | DescriptionDescription | DTL, Bengaluru, KarnatakaState lab | Mar 2026 |
| Sodium Bicarbonate Tablets I.P. 1000 mg | Batch T-2504229Mfg Apr 2025 · Exp Mar 2027 | The sample received does not conform to I.P. 2022 with respect to the test for DisintegrationDisintegration | CDTL, MumbaiCDSCO lab | Feb 2026 |
| Ambroxol Hydrochloride, Guaiphenesin & Terbutaline Sulphate Syrup | Batch L-2508007Mfg Aug 2025 · Exp Jul 2027 | The sample does not conform to claim as per Patent and Proprietary in respect to the Test of Total fungal countOther | RDTL, ChandigarhCDSCO lab | Feb 2026 |
| Ambroxol Hydrochloride, Guaiphenesin & Terbutaline Sulphate Syrup | Batch L-2508003Mfg Aug 2025 · Exp Jul 2027 | The sample does not conform to claim as per Patent and Proprietary in respect to the Test of Total fungal countOther | RDTL, ChandigarhCDSCO lab | Feb 2026 |
| Teneligliptin & Metformin Hydrochloride Extended-release Tablets 20mg and 500mg | Batch T-2406105Mfg Jun 2024 · Exp May 2026 | The sample received does not conform to I.P. 2022 with respect to the test of Dissolution (Teneligliptin) and Assay /Content of TeneligliptinAssay | CDTL, MumbaiCDSCO lab | Jan 2026 |
| Teneligliptin & Metformin Hydrochloride Extended-release Tablets 20mg and 500mg | Batch T-2509069Mfg Sep 2025 · Exp Aug 2027 | The sample received does not conform to I.P. 2022 with respect to the test for Dissolution (Teneligliptin)Dissolution | CDTL, MumbaiCDSCO lab | Jan 2026 |
| Clopidogrel Tablets IP 75 mg | Batch T-2405315Mfg May 2024 · Exp Apr 2026 | The sample received does not conform to IP 2022 specification with respect to the Description only.Description | CDTL, HyderabadCDSCO lab | Jan 2026 |
| Ciprofloxacin Tablets U.S.P. 500 mg.. | Batch T-2408090Mfg Aug 2024 · Exp Jul 2026 | The sample does not conform to claim as per U.S.P. with respect to the test for "Dissolution" of Ciprofloxacin.Dissolution | RDTL, GuwahatiCDSCO lab | Nov 2025 |
| CLOPIMEN-75 Clopidogrel Tablets IP 75 mg | Batch T-2405321Mfg May 2024 · Exp Apr 2026 | sample received does not conform to I.P. 2022 for the reason stated under description and with respect to the tests for Related substances" and "Assay.Assay | CDTL, MumbaiCDSCO lab | Sep 2025 |
| Onvin-4 MD Tablets (Ondansetron Orally Disintegrating Tablets IP 4 mg) | Batch RV24012Mfg May 2024 · Exp Apr 2026 | Test for Related SubstancesRelated substances | CDSCO, East Zone, KolkataCDSCO lab | Jun 2025 |
| Ondansertron Orally Disintegrating Tablets IP 4 mg (ONVIN-4 MD TABLETS) | Batch RV24012Mfg May 2024 · Exp Apr 2026 | Related SubstancesRelated substances | CDL, KolkataCDSCO lab | May 2025 |
| Sodium Bicarbonate Tablets U.S.P. 1000 mg | Batch T-2401309Mfg Jan 2024 · Exp Dec 2025 | "Description"Description | CDTL-MumbaiCDSCO lab | Mar 2025 |
| Sodium Bicarbonate Tablets U.S.P. 1000 mg (NABOSIS 1000 mg | Batch T-2307270Mfg Jul 2023 · Exp Jun 2025 | DescriptionDescription | CDTL HyderabadCDSCO lab | Feb 2025 |
| Ciprofloxacin Tablets U.S.P. 500 mg | Batch T-2401066Mfg Jan 2024 · Exp Dec 2025 | "Dissolution" of CiprofloxacinDissolution | RDTL GuwahatiCDSCO lab | Nov 2024 |
| Acicarb-650 | Batch T-2407400Mfg Jul 2024 · Exp Jun 2026 | sample does not conform to IP Specification for enteric coated tablets with respect to Disintegration in Acid stageDisintegration | DTL ChennaiState lab | Nov 2024 |
| Ciprofloxacin Tablets U.S.P. 500 mg | Batch T-2401066Mfg Jan 2024 · Exp Dec 2025 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Oct 2024 |
| Domperidone Tablets I.P. 10 mg | Batch T-2203140Mfg Mar 2022 · Exp Feb 2024 | Related SubstancesRelated substances | CDTL KolkataCDSCO lab | Mar 2023 |
| Domperidone Tablets I.P. 10 mg | Batch T-2203139Mfg Mar 2022 · Exp Feb 2024 | Related SubstancesRelated substances | CDTL KolkataCDSCO lab | Mar 2023 |
| Doxycycline Capsules I.P. 100 mg | Batch C-2106006Mfg Jun 2021 · Exp May 2023 | AssayAssay | CDL KolkataCDSCO lab | Mar 2022 |
| Calcium Citrate, Vitamin D3, Magnesium Hydroxide and Zinc Tablets (PROCAL TABLETS) | Batch T-2107091Mfg Jul 2021 · Exp Dec 2022 | Assay of Vitamin D3Assay | RDTL ChandigarhState lab | Feb 2022 |
| Ondansetron Orally Disintegrating Tablets IP 4 mg (ONVIN-4MD TABLETS) | Batch RV21023Mfg Jul 2021 · Exp Jun 2023 | DissolutionDissolution | RDTL ChandigarhCDSCO lab | Jan 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.